Drug Trial Radar · NCT03714373
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Oct 1, 2018
Primary completion
Aug 17, 2023
Study completion Aug 17, 2023
Sponsor
- Lead sponsor
- Soleno Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.
Conditions
- Prader-Willi Syndrome
Interventions
DCCRDrug
Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
DCCRDrug
Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
Placebo for DCCRDrug
Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the safety of DCCR by evaluating the incidence and severity of adverse events reportedTime frame: Baseline to end of OLE (up to 4 years)
- Change from RW Period Baseline in HQ-CT Total ScoreTime frame: RW Period Baseline to Week 16
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Irvine
Orange, California
Stanford University
Palo Alto, California
Rady Children's Hospital San Diego
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
University of Florida Gainesville
Gainesville, Florida
Emory Children's Center
Atlanta, Georgia
Indiana University School of Medicine
Indianapolis, Indiana
Kansas University Medical Center
Kansas City, Kansas
National Institutes of Health Hatfield Clinical Research Center
Bethesda, Maryland
Boston Children's Hospital
Boston, Massachusetts
Sparrow Clinical Research Institute
Lansing, Michigan
Children's Minnesota
Saint Paul, Minnesota
St. Joseph's University Medical Center
Paterson, New Jersey
NYU Winthrop Hospital
Mineola, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Research Institute at Nationwide Children's Hospital
Columbus, Ohio
Vanderbilt University
Nashville, Tennessee
Research Institute of Dallas
Dallas, Texas
University of Utah
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
Birmingham Women's and Children's Hospital
Birmingham, United Kingdom
Fulbourn Hospital
Cambridge, United Kingdom
Aintree University Hospital NHS Foundation Trust
Liverpool, United Kingdom
Royal London Hospital
London, United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
The Queen Elizabeth University
Glasgow, Scottland, United Kingdom
Hull and East Yorkshire Hospitals NHS Trust
Hull, Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.